JP2022095872A5 - - Google Patents

Download PDF

Info

Publication number
JP2022095872A5
JP2022095872A5 JP2022066071A JP2022066071A JP2022095872A5 JP 2022095872 A5 JP2022095872 A5 JP 2022095872A5 JP 2022066071 A JP2022066071 A JP 2022066071A JP 2022066071 A JP2022066071 A JP 2022066071A JP 2022095872 A5 JP2022095872 A5 JP 2022095872A5
Authority
JP
Japan
Prior art keywords
human insulin
insulin analogue
zinc complex
acylated derivative
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022066071A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022095872A (ja
Filing date
Publication date
Priority claimed from JP2019503703A external-priority patent/JP7432361B2/ja
Application filed filed Critical
Publication of JP2022095872A publication Critical patent/JP2022095872A/ja
Publication of JP2022095872A5 publication Critical patent/JP2022095872A5/ja
Pending legal-status Critical Current

Links

JP2022066071A 2016-08-02 2022-04-13 ヒトインスリンまたはそのアナログのアシル化誘導体 Pending JP2022095872A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN201610625257 2016-08-02
CN201610625257.5 2016-08-02
CN201610779132 2016-08-31
CN201610779132.8 2016-08-31
JP2019503703A JP7432361B2 (ja) 2016-08-02 2017-08-01 ヒトインスリンまたはそのアナログのアシル化誘導体
PCT/CN2017/095377 WO2018024186A1 (zh) 2016-08-02 2017-08-01 一种人胰岛素或其类似物的酰化衍生物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019503703A Division JP7432361B2 (ja) 2016-08-02 2017-08-01 ヒトインスリンまたはそのアナログのアシル化誘導体

Publications (2)

Publication Number Publication Date
JP2022095872A JP2022095872A (ja) 2022-06-28
JP2022095872A5 true JP2022095872A5 (enExample) 2022-12-08

Family

ID=61074099

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019503703A Active JP7432361B2 (ja) 2016-08-02 2017-08-01 ヒトインスリンまたはそのアナログのアシル化誘導体
JP2022066071A Pending JP2022095872A (ja) 2016-08-02 2022-04-13 ヒトインスリンまたはそのアナログのアシル化誘導体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019503703A Active JP7432361B2 (ja) 2016-08-02 2017-08-01 ヒトインスリンまたはそのアナログのアシル化誘導体

Country Status (6)

Country Link
US (1) US10815287B2 (enExample)
EP (1) EP3495384A4 (enExample)
JP (2) JP7432361B2 (enExample)
CN (2) CN114478747B (enExample)
TW (1) TWI747929B (enExample)
WO (1) WO2018024186A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019149245A1 (zh) * 2018-02-01 2019-08-08 江苏恒瑞医药股份有限公司 含人胰岛素类似物的酰化衍生物的药物组合物及其制备方法
US20210032307A1 (en) 2018-02-09 2021-02-04 Jiangsu Hengrui Medicine Co., Ltd. Codon optimized precursor gene and signal peptide gene of human insulin analogue
KR20210016400A (ko) 2018-05-24 2021-02-15 지앙수 헨그루이 메디슨 컴퍼니 리미티드 재조합 인간 인슐린 또는 그 유사체의 전구체를 제조하는 방법
TW202039437A (zh) 2018-12-11 2020-11-01 法商賽諾菲公司 肽黏合劑
BR112022013009A2 (pt) 2019-12-30 2022-09-06 Gan & Lee Pharmaceuticals Co Ltd Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina
CN116583531A (zh) * 2020-11-27 2023-08-11 江苏恒瑞医药股份有限公司 一种制备胰岛素或其类似物的酰化衍生物的方法
CN112939771A (zh) * 2021-01-28 2021-06-11 宁夏蓝博思化学技术有限公司 长链烷基二酸单叔丁酯的制备方法
CA3217734A1 (en) * 2021-05-24 2022-12-01 Baoye ZHENG A novel acylated insulin analog
WO2022268208A1 (zh) 2021-06-25 2022-12-29 甘李药业股份有限公司 含酰化胰岛素的药物组合物
WO2023143458A1 (zh) 2022-01-28 2023-08-03 甘李药业股份有限公司 酰化胰岛素
WO2025098457A1 (zh) 2023-11-07 2025-05-15 甘李药业股份有限公司 用于降糖的酰化胰岛素
CN117756914B (zh) * 2023-12-15 2024-09-03 瀚晖制药有限公司 依柯胰岛素的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ273285A (en) * 1993-09-17 1997-10-24 Novo Nordisk As Insulin derivatives and compositions thereof
CN1163574A (zh) * 1994-11-17 1997-10-29 伊莱利利公司 酰化的胰岛素类似物
US6310038B1 (en) * 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
US8003605B2 (en) * 2002-03-13 2011-08-23 Novo Nordisk A/S Minimising body weight gain in insulin treatment
ES2472421T3 (es) 2003-08-05 2014-07-01 Novo Nordisk A/S Nuevos derivados de insulina
AU2004261353B2 (en) * 2003-08-05 2009-12-10 Novo Nordisk A/S Novel insulin derivatives
EP1969004B1 (en) * 2005-12-28 2011-08-10 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
WO2009022006A1 (en) * 2007-08-15 2009-02-19 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
HUE032284T2 (en) * 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
US8935928B2 (en) * 2011-10-10 2015-01-20 Lockheed Martin Corporation Integrated air-cycle refrigeration and power generation system
CN104788556A (zh) * 2011-12-15 2015-07-22 上海恒瑞医药有限公司 人胰岛素类似物及其酰化衍生物
CN106496322A (zh) * 2015-09-07 2017-03-15 江苏恒瑞医药股份有限公司 人胰岛素或其类似物的酰化衍生物的制备方法
JP7523885B2 (ja) * 2016-02-05 2024-07-29 メモリアル スローン ケタリング キャンサー センター 幹細胞由来外胚葉系統前駆体を分化する方法

Similar Documents

Publication Publication Date Title
JP2019526537A5 (enExample)
EP3463293B1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5, une insuline prandiale et/ou une hormone gastrointestinale, et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
JP2011006428A5 (enExample)
JP2008528658A5 (enExample)
JP2019043957A5 (enExample)
US9018323B2 (en) Polymer derivative of cytidine metabolic antagonist
RU2008143668A (ru) Производное инсулина
WO2019110773A1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
JP2016523241A5 (enExample)
JP2020143066A5 (enExample)
JP2009536178A5 (enExample)
CA3084688A1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
US20240158445A1 (en) Cyclic cell-penetrating peptides with three or more hydrophobic residues
JP2010505741A5 (enExample)
KR20240171197A (ko) pI가 5.8 내지 8.5인 적어도 1종의 기저 인슐린, 및 카복실산염 전하 및 소수성 라디칼을 보유하는 코-폴리아미노산을 포함하는 pH 7의 주사용 용액
US20190169257A1 (en) Acylated derivative of human insulin or analogue thereof
RU2009122582A (ru) Пэг-модифицированный эксендин или аналог эксендина и его композиции и применение
RU2012128547A (ru) Дважды ацилированные производные glp-1
JP2012512901A5 (enExample)
JPH08508720A (ja) ピロールーアミジン化合物およびその薬剤的に受容できる塩、その製造法ならびにこれを含む医薬組成物
JP2024521757A5 (enExample)
LU86697A1 (fr) Nouveaux derives de la calcitonine,leur preparation et leur utilisation comme medicaments
WO2019243628A1 (fr) Composition injectable a ph 7 comprenant un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes et au moins une insuline basale presentant au moins un effet prandial et un effet basal
JP2009513562A5 (enExample)
JP2006513141A5 (enExample)